의사 여론조사 : 의사는 치료 지침으로 RWE(Real-World Evidence)를 지지

Doctors seem to widely recognise the value of real-world evidence (RWE) in clinical guidelines and treatment planning.

Regulators, pricing and reimbursement agencies, and organisations that produce clinical guidelines can draw on RWE - evidence generated outside of randomised controlled trials - but what impact is it having on practising physicians?

The poll asked 444 physicians from France, Germany, Italy, Spain, the UK and US who practise in cardiology, endocrinology, neurology, oncology and rheumatology about their knowledge and use of RWE.

Key Questions Answered:

• How would you rate your knowledge of RWE?
• How much do you agree or disagree with the following statement? ~RWE should be used to inform clinical guidelines.
• How much do you agree or disagree with the following statement? ~RWE should be used to inform clinical decision-support tools.
• How much value does RWE have for helping you to plan treatment programmes for your patients?
• How much do you agree or disagree with the following statement? ~RWE will become increasingly important when planning treatment programmes for your patients in five years' time.

Methodology:

Dossier reports are developed from independent and concise analysis derived from original industry surveys and in-depth interviews with industry thought leaders. Reports analyse in detail significant developments and market trends that pharma executives need to understand if they are to manage the opportunities and challenges that lie ahead. The focus of each report is defined by a review of the secondary literature and any knowledge gaps identified. Based on this initial research, an evidence-based and expert-informed discussion guide is developed to ensure the research answers the most critical questions. Additionally, robust screening criteria are established to ensure that those interviewed are qualified in terms of their experience, knowledge and stature to speak on the topic.

What makes our reports different?:

FirstWord Reports, a trusted industry leader with an exclusive focus on the pharmaceutical sector, delivers in-depth, actionable insights for biopharma professionals and decision-makers. Our deep industry knowledge enables us to provide relevant and valuable insights that help you identify emerging trends and navigate complex challenges effectively. Backed by extensive research and independent, impartial insights from leading experts and KOLs, our reports deliver the accuracy and reliability you need. With exclusive access to interviews and data unavailable elsewhere, along with ongoing market monitoring, we give you a comprehensive view of market dynamics. Covering over 40 dynamic disease areas and providing physician intelligence, including KOL insights and quantitative physician surveys, as well as industry expert views on issues in medical affairs, digital health, sales & marketing, market access, and other areas, our reports empower you to make smarter, data-driven decisions and maintain a competitive edge in a fast-moving industry.